DiaMedica Therapeutics Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 11, 2021 and accepted by EDGAR at Aug 11, 2021, 16:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2021-04-01 to 2021-06-30 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $4.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$7.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-04-01 to 2021-06-30 | $7.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-01 to 2021-06-30 | $14.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$3.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$6.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | −$0.17 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | −$0.37 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$6.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $13.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $2.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $21.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $21.8m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $1.4m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2021-06-30 | $20.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-21-019480. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.